COMPANY

Incyclix Bio

HQ: Durham, NC source · incyclixbio.com ↗ · Southeast

Keywords: oncology Breast Cancer Breast Cancer Metastatic Hormone Receptor Positive Tumor Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Ovarian Cancer CCNE1 Amplification INX-315

Location: Durham, NC · source · Oct 14, 2026

Profile checked Oct 10, 2026

$16.2MRaised (2 yrs)1Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $5M · announced Apr 8, 2026 Company release ↗
Source quote
- Apr 8, 2026 · Company release ↗
  “Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX- 315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors Additional $5 million from Hatteras Venture Partners supports advancement of Phase 1/2 clinical”
Raise Series B · $11.25M · announced Aug 25, 2025 Company release ↗
Source quote
- Aug 25, 2025 · Company release ↗
  “Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors Financing will enable the completion of the ongoing Phase 1/2 clinical trial of INX-315 in”
Deal Lilly deal · amount not disclosed · announced Nov 18, 2024 Company release ↗
Source quote
- Nov 18, 2024 · Company release ↗
  “Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio ® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer INX-315”

Raises announced in these releases: $16.25M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Apr 8, 2026 Raise Private equity round — Series B: $5M (total, as published), announced Apr 8, 2026. Source: company's own press page. source ↗
Apr 8, 2026 Raise Series B · $5M source ↗
Aug 25, 2025 Raise Private equity round — Series B Extension: $11.25M (total, as published), announced Aug 25, 2025. Source: company's own press page. source ↗
Aug 25, 2025 Raise Series B · $11.25M source ↗
Nov 18, 2024 Partnership Partnership / licensing announced Nov 18, 2024. Source: company's own press page. source ↗
Mar 28, 2023 Trial start Phase 1/Phase 2: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer source ↗

Upcoming milestones

2027-07 (ESTIMATED) · Phase 1/Phase 2 · Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer · NCT05735080

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $16.2M. Last 2 years.

Apr 8, 2026 Private equity round — Series B: $5M (total, as published), announced Apr 8, 2026. Source: company's own press page. source ↗
Aug 25, 2025 Private equity round — Series B Extension: $11.25M (total, as published), announced Aug 25, 2025. Source: company's own press page. source ↗
Nov 18, 2024 Partnership / licensing announced Nov 18, 2024. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05735080	Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer	Phase 1/Phase 2	Recruiting	Mar 28, 2023	2027-07 (estimated)